July 29, 2021 10:59 AM EDT
Financing

Three more com­pa­nies price IPOs, bring­ing this year's raise up to $11.78B

Nicole DeFeudis

Editor

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio ends de­vel­op­ment of gene ther­a­py for adren­al gland dis­or­der

Sanofi, Re­gen­eron to re­file Dupix­ent for skin con­di­tion af­ter new study win

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Ra­di­ant Bio snags $35M for an­ti­body plat­form, with GSK and Re­gen­eron part­ner­ships

Novo's oral amy­cretin could lead to more weight loss be­yond 12 weeks, ac­cord­ing to ear­ly-stage tri­al

GSK dis­con­tin­ues her­pes ther­a­peu­tic vac­cine af­ter Phase 2 dis­ap­point­ment

A service from the Financial Times